Bayer rolls out big changes; 2024’s biotech IPO queue; Dupixent’s ‘next big thing’; 23andMe’s struggle with dual identity; and more

Bay­er rolls out big changes; 2024’s biotech IPO queue; Dupix­en­t’s ‘next big thing’; 23and­Me’s strug­gle with dual iden­ti­ty; and more Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here. We got one short week of rel­a­tive calm be­fore head­ing in­to Q4 and full-year earn­ings, as J&J is set to kick things off in a few days. Still catch­ing up to JPM news and in­sights? Be sure to check out record­ings of our full event in San Fran­cis­co. Unlock this article instantly by becoming a free subscriber. You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.